FV 100 free base

• CAT Number: R026686
• CAS Number: 956483-02-6
• Molecular Formula: C27H35N3O6
• Molecular Weight: 497.59
• Purity: ≥95%
• Synonyms: L-Valine 5’-Ester with 3-(2-Deoxy-β-D-erythro-pentofuranosyl)-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-2(3H)-one
• Target: Antibiotic
• Storage: Store at -20°C
• IUPAC Name: [(2R,3S,5R)-3-hydroxy-5-[2-oxo-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-3-yl]oxolan-2-yl]methyl (2S)-2-amino-3-methylbutanoate
• InChI: InChI=1S/C27H35N3O6/c1-4-5-6-7-17-8-10-18(11-9-17)21-12-19-14-30(27(33)29-25(19)36-21)23-13-20(31)22(35-23)15-34-26(32)24(28)16(2)3/h8-12,14,16,20,22-24,31H,4-7,13,15,28H2,1-3H3/t20-,22+,23+,24-/m0/s1
• InChIKey: FJRRWJMFUNGZBJ-RBVMOCNTSA-N
• SMILES: CCCCCC1=CC=C(C=C1)C2=CC3=CN(C(=O)N=C3O2)[C@H]4C[C@@H]([C@H](O4)COC(=O)[C@H](C(C)C)N)O

FV 100 free base（Cat No.:R026686）is a selective and potent inhibitor of the fatty acid amide hydrolase (FAAH) enzyme, which plays a crucial role in the metabolism of endocannabinoids and other lipid mediators. By inhibiting FAAH, FV 100 free base enhances the levels of endogenous cannabinoids, thereby modulating pain, inflammation, and other physiological processes. This compound is being explored for its potential in treating conditions such as chronic pain, anxiety, and neuroinflammation. FV 100 free base provides a promising tool for advancing therapeutic strategies targeting the endocannabinoid system.

Reference

1: De Clercq E. An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014. Acta Pharm Sin B. 2015 Nov;5(6):520-43. doi: 10.1016/j.apsb.2015.09.001. Epub 2015 Nov 2. Review. PubMed PMID: 26713268; PubMed Central PMCID: PMC4675811. 2: De SK, Hart JC, Breuer J. Herpes simplex virus and varicella zoster virus: recent advances in therapy. Curr Opin Infect Dis. 2015 Dec;28(6):589-95. doi: 10.1097/QCO.0000000000000211. PubMed PMID: 26524331. 3: Andrei G, Snoeck R. Advances in the treatment of varicella-zoster virus infections. Adv Pharmacol. 2013;67:107-68. doi: 10.1016/B978-0-12-405880-4.00004-4. Review. PubMed PMID: 23886000. 4: De Clercq E. A cutting-edge view on the current state of antiviral drug development. Med Res Rev. 2013 Nov;33(6):1249-77. doi: 10.1002/med.21281. Epub 2013 Mar 11. Review. PubMed PMID: 23495004. 5: De Clercq E. Selective anti-herpesvirus agents. Antivir Chem Chemother. 2013 Jan 23;23(3):93-101. doi: 10.3851/IMP2533. Review. PubMed PMID: 23343513. 6: Hong SA, Kim K, Kim MK. Trends in the inequality of fruit and vegetable consumption between education levels indicated by the Korea National Health and Nutrition Examination Surveys. Eur J Clin Nutr. 2012 Aug;66(8):942-9. doi: 10.1038/ejcn.2012.39. Epub 2012 Apr 25. PubMed PMID: 22535135. 7: De Clercq E. Ten paths to the discovery of antivirally active nucleoside and nucleotide analogues. Nucleosides Nucleotides Nucleic Acids. 2012 Apr;31(4):339-52. doi: 10.1080/15257770.2012.657383. PubMed PMID: 22444195. 8: Price NB, Prichard MN. Progress in the development of new therapies for herpesvirus infections. Curr Opin Virol. 2011 Dec;1(6):548-54. doi: 10.1016/j.coviro.2011.10.015. Review. PubMed PMID: 22162744; PubMed Central PMCID: PMC3230035. 9: Andrei G, Snoeck R. Emerging drugs for varicella-zoster virus infections. Expert Opin Emerg Drugs. 2011 Sep;16(3):507-35. doi: 10.1517/14728214.2011.591786. Epub 2011 Jun 24. Review. PubMed PMID: 21699441. 10: Pentikis HS, Matson M, Atiee G, Boehlecke B, Hutchins JT, Patti JM, Henson GW, Morris A. Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers. Antimicrob Agents Chemother. 2011 Jun;55(6):2847-54. doi: 10.1128/AAC.01446-10. Epub 2011 Mar 28. PubMed PMID: 21444712; PubMed Central PMCID: PMC3101458.